Check here to see what new data we are researching and the latest enhancements we are making to our customer data:
As of 1 April 2020, following a series of mergers, there are now 135 CCGs in England. This is a significant milestone in the journey towards integrated care. Wilmington Healthcare’s customer data covers these organisational changes and we are also updating our England Commissioning Map to reflect the new shape of the CCG landscape.
We have significantly increased the coverage of our private hospital data. We have over 15,000 key decision makers and clinical staff within private hospitals and private hospital headquarters. Including, coverage of doctors working in a number of therapy areas such as oncology, trauma & orthopedics, respiratory, urology, ophthalmology and many more.
Our data in this area is fully updated and validated – giving you both insight on and access to key decision makers in the private healthcare sector.
Cancer Alliances and Radiotherapy Networks
We hold contact data on all cancer alliances and cancer alliance board members. We can also identify cancer alliance stakeholders by sub specialty, across 26 cancer types.
During 2019, 11 Radiotherapy Networks were established in England. The networks facilitate meaningful partnership working, involving groups of NHS trusts and cancer alliances. Their role is to improve care for patients by linking up cancer teams across sites and standardising processes. All 11 Radiotherapy Networks are now reflected in our data, each with a named Chair.
To find out more about our oncology data and offering click here.
For renal dialysis, we have added the NHS and private locations that act as main or satellite dialysis units. Typically, patients are initially assessed and treated at a main site, then referred to a satellite site for ongoing treatment.
The 100,000 Genomes Project, led by Genomics England in partnership with NHS England aims to bring the benefits of personalised medicine to the NHS. Our genomics data includes key organisations and responsibilities involved in the implementation of genomic medicine policy at a national and regional level including; National Genomic Board, Genomic Laboratory Hubs and Genomics England.